Zenshiro Tamaki1, Yoshihide Asano2, Masahide Kubo3, Hironobu Ihn4, Yayoi Tada5, Makoto Sugaya1, Takafumi Kadono1, Shinichi Sato1. 1. Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan. 2. Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan. Electronic address: yasano-tky@umin.ac.jp. 3. Department of Dermatology, Tokyo Kousei-Nenkin Hospital, Tokyo, Japan. 4. Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan. 5. Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
Abstract
BACKGROUND: Rapamycin has been shown to exert an anti-fibrotic effect on skin fibrosis in a certain subset of patients with systemic sclerosis (SSc) and in bleomycin-treated animal models. OBJECTIVES: To investigate the mechanism responsible for the anti-fibrotic effect of rapamycin especially by focusing on human α2(I) collagen (COL1A2) and matrix metalloproteinase 1 (MMP1) genes in normal and systemic sclerosis (SSc) dermal fibroblasts. METHODS: The expression levels of type I procollagen and MMP1 proteins were analyzed by immunoblotting and the mRNA levels of COL1A2 and MMP1 genes were evaluated by quantitative real-time RT-PCR. The activities of COL1A2 and MMP1 promoters were determined by reporter analysis. RESULTS: Rapamycin significantly decreased the levels of type I procollagen protein and COL1A2 mRNA, while significantly increasing the levels of MMP1 protein and mRNA in normal dermal fibroblasts. Similar effects of rapamycin were also observed in SSc dermal fibroblasts. Importantly, the inhibitory and stimulatory effects of rapamycin on the mRNA levels of COL1A2 and MMP1 genes, respectively, were significantly greater in SSc dermal fibroblasts than in normal dermal fibroblasts. In SSc dermal fibroblasts, rapamycin affected the expression of COL1A2 gene at the post-transcriptional level. In contrast, rapamycin altered the expression of MMP1 gene at the transcriptional level through the JNK/c-Jun signaling pathway in those cells. CONCLUSION: Rapamycin has a potential to directly regulate the deposition of type I collagen in extracellular matrix through inhibiting type I collagen synthesis and promoting its degradation by MMP1, suggesting that this drug is useful for the treatment of SSc.
BACKGROUND:Rapamycin has been shown to exert an anti-fibrotic effect on skin fibrosis in a certain subset of patients with systemic sclerosis (SSc) and in bleomycin-treated animal models. OBJECTIVES: To investigate the mechanism responsible for the anti-fibrotic effect of rapamycin especially by focusing on human α2(I) collagen (COL1A2) and matrix metalloproteinase 1 (MMP1) genes in normal and systemic sclerosis (SSc) dermal fibroblasts. METHODS: The expression levels of type I procollagen and MMP1 proteins were analyzed by immunoblotting and the mRNA levels of COL1A2 and MMP1 genes were evaluated by quantitative real-time RT-PCR. The activities of COL1A2 and MMP1 promoters were determined by reporter analysis. RESULTS:Rapamycin significantly decreased the levels of type I procollagen protein and COL1A2 mRNA, while significantly increasing the levels of MMP1 protein and mRNA in normal dermal fibroblasts. Similar effects of rapamycin were also observed in SSc dermal fibroblasts. Importantly, the inhibitory and stimulatory effects of rapamycin on the mRNA levels of COL1A2 and MMP1 genes, respectively, were significantly greater in SSc dermal fibroblasts than in normal dermal fibroblasts. In SSc dermal fibroblasts, rapamycin affected the expression of COL1A2 gene at the post-transcriptional level. In contrast, rapamycin altered the expression of MMP1 gene at the transcriptional level through the JNK/c-Jun signaling pathway in those cells. CONCLUSION:Rapamycin has a potential to directly regulate the deposition of type I collagen in extracellular matrix through inhibiting type I collagen synthesis and promoting its degradation by MMP1, suggesting that this drug is useful for the treatment of SSc.
Authors: Garret Ma; Idris Samad; Kevin Motz; Linda X Yin; Madhavi V Duvvuri; Dacheng Ding; Daryan R Namba; Jennifer H Elisseeff; Maureen R Horton; Alexander T Hillel Journal: Laryngoscope Date: 2016-09-01 Impact factor: 3.325
Authors: Daryan R Namba; Garret Ma; Idris Samad; Dacheng Ding; Vinciya Pandian; Jonathan D Powell; Maureen R Horton; Alexander T Hillel Journal: Otolaryngol Head Neck Surg Date: 2015-03-09 Impact factor: 3.497
Authors: Christina G Katsiari; Theodora Simopoulou; Ioannis Alexiou; Lazaros I Sakkas Journal: Hum Vaccin Immunother Date: 2018-07-16 Impact factor: 3.452
Authors: Anupam Mitra; Jesus I Luna; Alina I Marusina; Alexander Merleev; Smriti Kundu-Raychaudhuri; David Fiorentino; Siba P Raychaudhuri; Emanual Maverakis Journal: J Invest Dermatol Date: 2015-07-02 Impact factor: 8.551